4 completed, 4 recruiting, 1 active not recruiting, 1 not yet recruiting. 10 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 4, Recruiting 4, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Immunome, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of IM-1340 in Participants With Advanced Cancer IM-1340 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Immunome, Inc. | 200 | 2026-11-01 | 2026-10-22 |
| A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer 177Lu-IM-3050 - Solid Malignancies | Phase 1 | Recruiting | Immunome, Inc. | 105 | 2026-06-19 | 2026-10-07 |
| A Phase 1 Study of IM-1617 in Participants With Advanced Cancer IM-1617 - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Immunome, Inc. | 175 | 2026-05-21 | 2026-09-29 |
| A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants Varegacestat Reference Formulation, Varegacestat Test Formulation A, Varegacestat Test Formulation B - Healthy | Phase 1 | Recruiting | Immunome, Inc. | 44 | 2026-05-21 | 2026-10-29 |
| A Varegacestat Hepatic Impairment Study varegacestat - Healthy Volunteer, Hepatic Impairment (HI) | Phase 1 | Completed | Immunome, Inc. | 35 | 2025-03-07 | 2026-03-10 |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer IM-1021 - Solid Malignancies, Hematologic Malignancies | Phase 1 | Recruiting | Immunome, Inc. | 190 | 2025-02-26 | 2026-08-10 |
| A Phase 1 Mass Balance Study of Varegacestat varegacestat - Healthy Volunteer | Phase 1 | Completed | Immunome, Inc. | 6 | 2025-02-25 | 2025-09-26 |
| A Cardiac Liability Study of Varegacestat in Healthy Participants varegacestat, Placebo, Moxifloxacin 400 mg - Healthy Volunteer | Phase 1 | Completed | Immunome, Inc. | 32 | 2025-02-24 | 2025-09-24 |
| A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants varegacestat, Itraconazole (200 mg) - Healthy Volunteer | Phase 1 | Completed | Immunome, Inc. | 22 | 2024-11-11 | 2025-05-11 |
| IMM-BCP-01 in Mild to Moderate COVID-19 IMM-BCP-01, Placebo - SARS-CoV2 Infection, COVID-19 | Phase 1 | Terminated | Immunome, Inc. | 9 | 2022-06-03 | 2024-09-26 |
| A Study of AL102 in Patients With Progressing Desmoid Tumors AL102, Placebo - Desmoid, Desmoid Tumor | Phase 2 / Phase 3 | Active not recruiting | Immunome, Inc. | 198 | 2021-09-01 | 2026-06-08 |
Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Breast Neoplasms (1) · COVID-19 (1) · Desmoid Tumors (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
IMM20184, IMM20190, and IMM20253 drug combination (1) · Itraconazole (1) · Moxifloxacin (1)
United States (10) · Spain (2) · Australia (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · United Kingdom (1)
Michelle Valentine (1) · Mrinal Gounder, MD (1)